3,000
Participants
Start Date
August 18, 2021
Primary Completion Date
June 14, 2026
Study Completion Date
June 14, 2026
brolucizumab
Prospective observational study. There is no treatment allocation. Patients administered brolucizumab, that have started before inclusion of the patient into the study will be enrolled.
RECRUITING
Novartis Investigative Site, Goyang-si
RECRUITING
Novartis Investigative Site, Suwon
RECRUITING
Novartis Investigative Site, Incheon
RECRUITING
Novartis Investigative Site, Daejeon
RECRUITING
Novartis Investigative Site, Taegu
RECRUITING
Novartis Investigative Site, Daegu
RECRUITING
Novartis Investigative Site, Busan
RECRUITING
Novartis Investigative Site, Busan
RECRUITING
Novartis Investigative Site, Busan
RECRUITING
Novartis Investigative Site, Gwangju
RECRUITING
Novartis Investigative Site, Gwangju
RECRUITING
Novartis Investigative Site, Jeju City
RECRUITING
Novartis Investigative Site, Daegu
RECRUITING
Novartis Investigative Site, Guri-si
RECRUITING
Novartis Investigative Site, Iksan Si
RECRUITING
Novartis Investigative Site, Daegu
RECRUITING
Novartis Investigative Site, Pusan
RECRUITING
Novartis Investigative Site, Seoul
RECRUITING
Novartis Investigative Site, Seoul
RECRUITING
Novartis Investigative Site, Seoul
RECRUITING
Novartis Investigative Site, Seoul
RECRUITING
Novartis Investigative Site, Seoul
RECRUITING
Novartis Investigative Site, Seoul
RECRUITING
Novartis Investigative Site, Seoul
RECRUITING
Novartis Investigative Site, Seoul
RECRUITING
Novartis Investigative Site, Seoul
RECRUITING
Novartis Investigative Site, Seoul
RECRUITING
Novartis Investigative Site, Seoul
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY